# Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

> **NCT01756157** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 47 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **BIOLOGICAL:** CINRYZE with rHuPH20

## Key facts

- **NCT ID:** NCT01756157
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-04
- **Primary completion:** 2013-09-13
- **Final completion:** 2013-09-13
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01756157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01756157, "Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01756157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*